Navigation Links
Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation

Most Up-to-Date Analysis of the Alzheimer's Disease Market Now Available

from Decision Resources

WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that with Myriad Genetics/Lundbeck's decision to discontinue the development of Flurizan, the most likely first-to-market disease-modifying Alzheimer's disease treatment becomes Elan/Wyeth's bapineuzumab, an anti-beta-amyloid monoclonal antibody, expected to launch in 2011. The recent Phase III failure of Flurizan underscores the risk involved with developing an agent for Alzheimer's disease.

Decision Resources also finds that both bapineuzumab and Eli Lilly's LY-2062430 will quickly become blockbusters shortly after their launch due to their efficacy and high price point. The widespread use of these agents will depend, in part, on their safety and the complementary use of new diagnosis techniques that would permit patients to be diagnosed in the early stages of the disease, when disease-modifying therapies provide the greatest therapeutic benefit.

"We await Phase III results of the bapineuzumab trials with great interest, both in terms of the drug's safety profile, but also its efficacy in Alzheimer's disease patients carrying the ApoEe4 gene (which is a risk factor in Alzheimer's disease) compared with non-ApoEe4 gene carriers," states Andrea Witt, Ph.D., director at Decision Resources. "Should efficacy prove poor in ApoEe4 gene carriers, patients will be faced with the difficult decision of whether they would want to know whether they carry this gene. Nevertheless, even if bapineuzumab benefits only the non-ApoEe4 gene carriers-a prospective population of 40 to 70 percent of Alzheimer's disease patients-bapineuzumab stands to reap considerable profits in the Alzheimer's disease market."

Two new Decision Resources Alzheimer's disease reports-the Pharmacor report entitled Alzheimer's Disease and Brands & Strategies: Alzheimer's Disease-have been updated to include new data and analysis on how the Alzheimer's disease market is impacted by the failure of Flurizan. Some of the key questions answered in the reports include:

-- How does the failure of Flurizan impact the current Alzheimer's disease

market competitors, and which companies benefit the most?

-- How will the absence of Flurizan change the performance of emerging

therapies? Will the overall Alzheimer's disease market expand or


-- How will Lundbeck weather the failure of Flurizan?

-- What impact will Flurizan's discontinuation have on the Alzheimer's

disease market over the 2007-2017 time period?

-- Which drug stands most to gain from Flurizan's discontinuation?

About Decision Resources

Decision Resources ( is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources


SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
2. Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy
3. Family of Three Americans Become Pain Free and Improve Their Quality of Life With Stem Cell Treatment in Mexico
4. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
5. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
6. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
7. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
8. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
11. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
(Date:11/27/2015)... ... 27, 2015 , ... Keeping in mind challenges faced by ... wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for ... parents and bring advice from parenting experts within their reach. As a part ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... November 26, 2015 , ... The ... bioavailability and the need to integrate dose form selection in early phase drug ... the membership organization supporting and bringing together the UK’s emerging life sciences companies, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Health-E-minds ... collaborated with Women’s Web – an online resource for Indian women looking ... and emotional well-being relationship, life balance, stress, professional development, and lifestyle. Health-E-minds ...
Breaking Medicine News(10 mins):